
BEIJING -- Ustar, a Chinese point of care (POC) startup that designs molecular diagnostic systems, has raised about 300 million yuan ($2.6 million) in a Series E+ funding round.
The investment was led by CPE Yuanfeng. Current Ustar shareholder Oriental Fortune Capital also made an additional investment.